Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Beyond Meat Shares Plunge on Dismal Earnings and Bleak Outlook

Dieter Jaworski by Dieter Jaworski
November 11, 2025
in Analysis, Consumer & Luxury, Earnings
0
Beyond Meat Stock
0
SHARES
8
VIEWS
Share on FacebookShare on Twitter

Beyond Meat’s stock experienced a severe downturn in after-hours trading, plummeting more than 8% following the release of catastrophic quarterly results and a grim forecast that shattered investor hopes for a near-term recovery.

A Quarter of Significant Losses and Declining Revenue

The plant-based meat producer reported a net loss of $110.7 million for the third quarter of 2025, a dramatic increase from the $26.6 million loss recorded during the same period last year. Revenue fell 13.3% to $70.2 million. A particularly alarming development was the collapse of the company’s gross margin, which dropped to just 10.3% from 17.7% previously.

Key financial highlights from the report include:
– Net loss ballooned to $110.7 million
– Revenue declined to $70.2 million, a 13.3% drop
– Gross margin contracted by 7.4 percentage points
– The company recorded a $77.4 million impairment charge on its assets

Gloomy Forecast Deepens Investor Concerns

The outlook provided for the fourth quarter offers little comfort to shareholders. Beyond Meat anticipates revenue of just $60 to $65 million, falling significantly short of the $70 million that market analysts had projected. This guidance suggests the company itself expects its sales slump to continue.

Should investors sell immediately? Or is it worth buying Beyond Meat?

While CEO Ethan Brown pointed to improvements in the company’s balance sheet structure, persistently weak demand in core markets like the United States and Europe tells a different story. The central question remains whether the pioneering plant-based meat company can successfully navigate this challenging period.

Segment Performance Shows Widespread Weakness

The company’s struggles extend across nearly all business segments. U.S. retail sales dropped 18.4%, while U.S. foodservice revenue declined 27.3%. Internationally, retail sales also decreased by 4.6%. The sole bright spot was a minimal 2.3% increase in international foodservice revenue.

Investors now face a critical juncture: Is this a temporary downturn for a former market darling, or does it signal a more permanent decline? The upcoming conference call with investors is likely to provide crucial insights into the company’s future trajectory.

Ad

Beyond Meat Stock: Buy or Sell?! New Beyond Meat Analysis from February 7 delivers the answer:

The latest Beyond Meat figures speak for themselves: Urgent action needed for Beyond Meat investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Beyond Meat: Buy or sell? Read more here...

Tags: Beyond Meat
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Graftech Stock
Commodities

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026
Next Post
D-Wave Quantum Stock

D-Wave Quantum Shares Face Mounting Pressure

RWE PK Stock

RWE's Pivotal Earnings Report Approaches

Lynas Stock

Lynas Capitalizes on Western Shift From Chinese Rare Earth Dominance

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com